|
NRBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.85159731570207E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4475998177943E-10 |
| Normal-vs-Stage2 |
4.478400E-01 |
| Normal-vs-Stage3 |
8.17769999494899E-08 |
| Normal-vs-Stage4 |
2.05009999976191E-07 |
| Stage1-vs-Stage2 |
2.141600E-03 |
| Stage1-vs-Stage3 |
7.617800E-01 |
| Stage1-vs-Stage4 |
8.129400E-01 |
| Stage2-vs-Stage3 |
4.377600E-03 |
| Stage2-vs-Stage4 |
7.604300E-03 |
| Stage3-vs-Stage4 |
9.563800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.60145246958155E-12 |
| Normal-vs-AfricanAmerican |
2.014500E-04 |
| Normal-vs-Asian |
3.43710000016983E-07 |
| Caucasian-vs-AfricanAmerican |
1.852620E-01 |
| Caucasian-vs-Asian |
4.426200E-01 |
| AfricanAmerican-vs-Asian |
9.882500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.69330000033119E-07 |
| Normal-vs-Female |
3.71029984513882E-10 |
| Male-vs-Female |
7.795400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.98219995972693E-10 |
| Normal-vs-Age(41-60Yrs) |
2.43819997525208E-09 |
| Normal-vs-Age(61-80Yrs) |
8.880100E-03 |
| Normal-vs-Age(81-100Yrs) |
1.186210E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.523800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.139600E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.843800E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.859590E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.315600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.965400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.120960E-01 |
| Classical-VS-Follicular |
<1E-12 |
| Classical-VS-Other |
4.531800E-01 |
| Classical-VS-Normal |
1.62525548574877E-12 |
| Tall-VS-Follicular |
1.9032999620805E-09 |
| Tall-VS-Other |
2.427200E-01 |
| Tall-VS-Normal |
3.06710001840571E-09 |
| Follicular-VS-Other |
1.433580E-01 |
| Follicular-VS-Normal |
1.646200E-01 |
| Other-VS-Normal |
4.724400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.790100E-04 |
| Normal-vs-N1 |
4.047900E-04 |
| N0-vs-N1 |
3.146600E-01 |
|
|
